Published in Prenat Diagn on April 30, 2014
Non-invasive prenatal testing: a review of international implementation and challenges. Int J Womens Health (2015) 0.96
Non-Invasive Prenatal Testing Using Cell Free DNA in Maternal Plasma: Recent Developments and Future Prospects. J Clin Med (2014) 0.85
Implementation of non-invasive prenatal testing by semiconductor sequencing in a genetic laboratory. Prenat Diagn (2016) 0.75
Prenatal Screening Using Maternal Markers. J Clin Med (2014) 0.75
Performance evaluation of the NeoBona test, a new paired-end massive parallel shotgun sequencing approach for cfDNA based aneuploidy screening. Ultrasound Obstet Gynecol (2016) 0.75
NIPTRIC: an online tool for clinical interpretation of non-invasive prenatal testing (NIPT) results. Sci Rep (2016) 0.75
Bioinformatics Approaches for Fetal DNA Fraction Estimation in Noninvasive Prenatal Testing. Int J Mol Sci (2017) 0.75
Recommended practice for laboratory reporting of non-invasive prenatal testing (NIPT) of trisomies 13, 18 and 21: a consensus opinion. Prenat Diagn (2017) 0.75
Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. Lancet (2006) 6.78
Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med (2015) 6.12
Position statement from the Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenat Diagn (2013) 2.87
Estimates of penetrance for recurrent pathogenic copy-number variations. Genet Med (2012) 2.86
Contingent screening for Down syndrome is an efficient alternative to non-disclosure sequential screening. Prenat Diagn (2004) 2.71
Frequency of Down's syndrome and neural-tube defects in the same family. Lancet (2003) 2.21
Prenatal Detection of Down Syndrome using Massively Parallel Sequencing (MPS): a rapid response statement from a committee on behalf of the Board of the International Society for Prenatal Diagnosis, 24 October 2011. Prenat Diagn (2012) 1.45
Three-stage contingent screening for Down syndrome. Prenat Diagn (2006) 1.45
Single-nucleotide polymorphism-based noninvasive prenatal screening in a high-risk and low-risk cohort. Obstet Gynecol (2014) 1.44
First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol (2007) 1.27
Preconceptional and prenatal screening for fragile X syndrome: experience with 40,000 tests. Prenat Diagn (2007) 1.07
Obstetricians and gynecologists' practice and opinions of expanded carrier testing and noninvasive prenatal testing. Prenat Diagn (2013) 1.05
Mitochondrial dysfunction and Down's syndrome. Bioessays (2002) 1.04
Screening for Down syndrome using first-trimester combined screening followed by second-trimester ultrasound examination in an unselected population. Am J Obstet Gynecol (2006) 0.92
Aneuploidy screening: a position statement from a committee on behalf of the Board of the International Society for Prenatal Diagnosis, January 2011. Prenat Diagn (2011) 0.91
Practical strategies in contingent sequential screening for Down syndrome. Prenat Diagn (2005) 0.90
Maternal serum ADAM12 levels in Down and Edwards' syndrome pregnancies at 9-12 weeks' gestation. Prenat Diagn (2006) 0.87
Second trimester ultrasound prenasal thickness combined with nasal bone length: a new method of Down syndrome screening. Prenat Diagn (2005) 0.86
Model-predicted performance of second-trimester Down syndrome screening with sonographic prenasal thickness. J Ultrasound Med (2010) 0.85
Prenasal thickness in first-trimester screening for Down syndrome. Prenat Diagn (2012) 0.84
Maternal serum placental growth factor and α-fetoprotein testing in first trimester screening for Down syndrome. Prenat Diagn (2013) 0.81
Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol (2012) 0.80
First-trimester screening for Down syndrome in France combining fetal nuchal translucency measurement and biochemical markers. Prenat Diagn (2003) 0.80
First trimester Down syndrome screening with dried blood spots using a dual analyte free beta hCG and PAPP-A immunofluorometric assay. Prenat Diagn (2011) 0.78
Current controversies in prenatal diagnosis 1: screening for fragile X syndrome. Prenat Diagn (2012) 0.77
Screening for Down syndrome--incidental diagnosis of other aneuploidies. Prenat Diagn (2014) 0.77
Second trimester maternal serum ADAM12 levels in Down's syndrome pregnancies. Prenat Diagn (2008) 0.77
First-trimester screening for Down syndrome with ductus venosus Doppler studies in addition to nuchal translucency and serum markers. Prenat Diagn (2005) 0.76
Chromosomal abnormalities and birth defects among couples with colchicine treated familial Mediterranean fever. Am J Obstet Gynecol (2005) 0.76
Model predicted Down syndrome detection rates for nuchal translucency screening in twin pregnancies. Prenat Diagn (2011) 0.76
First trimester maternal serum placental protein 13 levels in singleton vs. twin pregnancies with and without severe pre-eclampsia. J Perinat Med (2013) 0.76
CT ratios: parameter estimates are inconsistent with SURUSS publications? Prenat Diagn (2006) 0.75
Response to "On gestational weeks and maths". Prenat Diagn (2013) 0.75
Advanced maternal age is no longer so advanced. Isr Med Assoc J (2005) 0.75
Response to Benn. Genet Med (2013) 0.75
Prenatal screening and diagnosis--An introduction. Am J Med Genet C Semin Med Genet (2007) 0.75
Maternal thyroid function at 11-13 weeks of gestation in fetal trisomies 21 and 18. Prenat Diagn (2011) 0.75
Correlation between nasal bone length and nuchal translucency thickness. Prenat Diagn (2007) 0.75
Maternal serum triple marker levels in immigrants to Israel from Ethiopia. Fetal Diagn Ther (2009) 0.75
Predicting the result of additional second-trimester markers from a woman's first-trimester marker profile: a new concept in Down syndrome screening. Prenat Diagn (2005) 0.75
Role of collagen type IV in the pathogenesis of increased prenasal thickness in Down syndrome fetuses: sonographic and immunohistological findings. J Perinat Med (2017) 0.75
Implementation of a national nuchal translucency education and quality monitoring program. Obstet Gynecol (2014) 0.75
[Prenatal diagnosis for chromosomal abnormality: time to change the Israeli policy]. Harefuah (2006) 0.75
Maternal serum inhibin levels in twin and singleton pregnancies conceived by assisted reproduction. Hum Reprod (2006) 0.75
Which contingent sequential screening protocol? Prenat Diagn (2005) 0.75
Case report: clinical utility of ultrasound nasal bone determination in the prenatal diagnosis of Down syndrome. Prenat Diagn (2003) 0.75
Down syndrome screening in assisted conception twins: an iatrogenic medical challenge. Obstet Gynecol Surv (2013) 0.75